ArticleJournal of immunology (Baltimore, Md. : 1950)2012
ZBTB32 is an early repressor of the CIITA and MHC class II gene expression during B cell differentiation to plasma cells.
Article in Journal of immunology (Baltimore, Md. : 1950), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 85 citations in OpenAlex.
- Heme enhances B-cell proliferation and plasma cell formation through reduced p21 and Rb expression.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Article
- Bank1 modulates the differentiation and molecular profile of key B cell populations in autoimmunity.JCI insight · 2024Article
- Sexual dimorphism in atherosclerotic plaques of aged LdlrImmunity & ageing : I & A · 2024Article
- Article
- Evaluation of Clinical and Immunological Alterations Associated with ICF Syndrome.Journal of clinical immunology · 2023Article
- Mapping the dynamic genetic regulatory architecture of HLA genes at single-cell resolution.Nature genetics · 2023Article
- Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analyses.Cell reports · 2023Article
- CRISPR/Cas9 editing reveals IRF8 regulated gene signatures restraining plasmablast differentiation.Heliyon · 2023Article
- Mapping the dynamic genetic regulatory architecture ofmedRxiv : the preprint server for health sciences · 2023Article
- Effect of a Fructose-Rich Diet on Gut Microbiota and Immunomodulation: Potential Factors for Multiple Sclerosis.ImmunoHorizons · 2023Article
- H3K27me3 Demethylase UTX Restrains Plasma Cell Formation.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- DNA-double strand breaks enhance the expression of major histocompatibility complex class II through the ATM-NF-κΒ-IRF1-CIITA pathway.Cancer gene therapy · 2022Article
- Activated B Cells and Plasma Cells Are Resistant to Radiation Therapy.International journal of radiation oncology, biology, physics · 2022Article
- Resident Memory B Cells in Barrier Tissues.Frontiers in immunology · 2022Review
- Single-cell gene expression analysis of cryopreserved equine bronchoalveolar cells.Frontiers in immunology · 2022Article
- Inhibition of H3K27me3 Demethylases Promotes Plasmablast Formation.ImmunoHorizons · 2021Article
- Attenuated activation of pulmonary immune cells in mRNA-1273-vaccinated hamsters after SARS-CoV-2 infection.The Journal of clinical investigation · 2021Article
- An IRF4-MYC-mTORC1 Integrated Pathway Controls Cell Growth and the Proliferative Capacity of Activated B Cells during B Cell Differentiation In Vivo.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- The Murine MHC Class II Super EnhancerJournal of immunology (Baltimore, Md. : 1950) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
CIITA and MHC class II expression is silenced during the differentiation of B cells to plasma cells. When B cell differentiation is carried out ex vivo, CIITA silencing occurs rapidly, but the factors contributing to this event are not known. ZBTB32, also known as repressor of GATA3, was identified as an early repressor of CIITA in an ex vivo plasma cell differentiation model. ZBTB32 activity occurred at a time when B lymphocyte-induced maturation protein-1 (Blimp-1), the regulator of plasma cell fate and suppressor of CIITA, was minimally induced. Ectopic expression of ZBTB32 suppressed CIITA and I-A gene expression in B cells. Short hairpin RNA depletion of ZBTB32 in a plasma cell line resulted in re-expression of CIITA and I-A. Compared with conditional Blimp-1 knockout and wild-type B cells, B cells from ZBTB32/ROG-knockout mice displayed delayed kinetics in silencing CIITA during ex vivo plasma cell differentiation. ZBTB32 was found to bind to the CIITA gene, suggesting that ZBTB32 directly regulates CIITA. Lastly, ZBTB32 and Blimp-1 coimmunoprecipitated, suggesting that the two repressors may ultimately function together to silence CIITA expression. These results introduce ZBTB32 as a novel regulator of MHC-II gene expression and a potential regulatory partner of Blimp-1 in repressing gene expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.